Cargando…

Role of the UGT2B17 deletion in exemestane pharmacogenetics

Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of breast cancer. The major metabolic pathway for EXE is reduction to form the active 17β-dihydro-EXE (17β-DHE) and subsequent glucuronidation to 17β-hydroxy-EXE-17-O-β-D-glucuronide (17β-DHE-Gluc) by UGT2B17. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Shaman, Chen, Gang, Truica, Cristina, Baird, Cynthia C., Leitzel, Kim, Lazarus, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700874/ https://www.ncbi.nlm.nih.gov/pubmed/28534527 http://dx.doi.org/10.1038/tpj.2017.18

Ejemplares similares

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Impact of UGT2B17 gene deletion on the steroid profile of an athlete
por: Martín‐Escudero, Pilar, et al.
Publicado: (2015)

The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety
por: Ching, Nathan R, et al.
Publicado: (2018)

In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β‐dihydroexemestane
por: Peterson, Amity, et al.
Publicado: (2017)

Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives
por: Peterson, Amity, et al.
Publicado: (2017)

Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018)

Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver
por: Sutliff, Aimee K., et al.
Publicado: (2019)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Publicado: (2015)

Meta-Analysis Reveals a Lack of Association between UGT2B17 Deletion Polymorphism and Tumor Susceptibility
por: Deng, Xiaheng, et al.
Publicado: (2014)

Pharmacogenetics of uridine diphosphate glucuronosyltransferase (UGT2B7) genetic polymorphism on valproic acid pharmacokinetics in epilepsy
por: Munisamy, Murali, et al.
Publicado: (2014)

The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions
por: Marques, Sara Correia, et al.
Publicado: (2010)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma
por: Mafune, Aki, et al.
Publicado: (2015)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p
por: Sutliff, Aimee K., et al.
Publicado: (2019)

UGT1A1 (TA)(n) Promoter Genotype: Diagnostic and Population Pharmacogenetic Marker in Serbia
por: Vukovic, M, et al.
Publicado: (2018)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants
por: Sun, Dongxiao, et al.
Publicado: (2006)

Red wine and component flavonoids inhibit UGT2B17 in vitro
por: Jenkinson, Carl, et al.
Publicado: (2012)

UGT2B17 modifies drug response in chronic lymphocytic leukaemia
por: Allain, Eric P., et al.
Publicado: (2020)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

UGT2B17 Polymorphism and Risk of Prostate Cancer: A Meta-Analysis
por: Kpoghomou, Marce-Amara, et al.
Publicado: (2013)

Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Papamichos, Spyros I., et al.
Publicado: (2020)

Whole exome sequencing identifies hemizygous deletions in the UGT2B28 and USP17L2 genes in a three-generation family with endometriosis
por: Albertsen, Hans M., et al.
Publicado: (2019)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment
por: Amaral, Cristina, et al.
Publicado: (2012)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Carbonyl reduction of NNK by recombinant human lung enzymes: identification of HSD17β12 as the reductase important in (R)-NNAL formation in human lung
por: Ashmore, Joseph H, et al.
Publicado: (2018)

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro
por: Salhab, Hassan, et al.
Publicado: (2021)

A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome
por: Wagner, Antoine, et al.
Publicado: (2023)

Polymorphisms of estrogen metabolism-related genes ESR1, UGT2B17, and UGT1A1 are not associated with osteoporosis in surgically menopausal Japanese women
por: Yokota, Megumi, et al.
Publicado: (2015)

Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism
por: Strahm, Emmanuel, et al.
Publicado: (2013)

A review of the use of exemestane in early breast cancer
por: Robinson, Andrew
Publicado: (2009)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5g5urq5hd71310u8hs017ijnv2